Table 1.
RP of EGFR-TKIs related studies
| Drugs | Study | Published year | study type | No. of cases | Radiation dose(Gy) | RP rate(%) |
|---|---|---|---|---|---|---|
| First-generation EGFR-TKIs | Xu K [41] | 2021 | Retrospective study | 45 | 50–66 | 37.7 |
| Chih-Chia Chang [42] | 2011 | Clinical Trial | 25 | 40–50 |
84.0 > 3Grade: 12.0 |
|
| Caicun Zhou [43] | 2018 | Retrospective study | 145 | 33–60 | > 3Grade: 7.7 | |
| Jianguo Sun [44] | 2019 | Clinical Trial | 10 | 54–60 |
40.0 > 3Grade: 20.0 |
|
| Wenxiao Jia [49] | 2021 | Retrospective study | 67 | 50–60 |
44.78 > 3Grade: 8.9 |
|
| C Yong [45] | 2016 | Clinical Trial | 316 | 40–65 | 15.1 | |
| Erlotinib | Zhuang H [46] | 2014 | Retrospective study | 24 | 44–46 |
36.0 > 3Grade: 21.0 |
| Gefitinib | Rothschild S [47] | 2011 | Clinical Trial | 14 | 63 | 14.0 |
| Okamoto I [48] | 2011 | Clinical Trial | 9 | 60 | 28.0 | |
| Oxitinib | Wenxiao Jia [57] | 2021 | Retrospective study | 11 | 60 | 63.6 |
| Crizotinib | Hou H [61] | 2019 | Meta-analysis | / | / | 4.2 |
RP Radiation pneumonitis, EGFR-TKI Epidermal Growth Factor Receptor-Tyrosine Kinase inhibitor